


FzM1.8

Cat. No.:	HY-117163		
CAS No.:	2204290-85-5		
Molecular Formula:	C ₁₈ H ₁₄ N ₂ O ₄		
Molecular Weight:	322.31		
Target:	Wnt; β -catenin		
Pathway:	Stem Cell/Wnt		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro	DMSO : 83.33 mg/mL (258.54 mM; Need ultrasonic)			
		Solvent Concentration	Mass	
			1 mg	5 mg
	Preparing Stock Solutions		10 mg	
	1 mM	3.1026 mL	15.5130 mL	31.0260 mL
	5 mM	0.6205 mL	3.1026 mL	6.2052 mL
	10 mM	0.3103 mL	1.5513 mL	3.1026 mL
Please refer to the solubility information to select the appropriate solvent.				
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: \geq 2.08 mg/mL (6.45 mM); Clear solution			
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE- β -CD in saline) Solubility: \geq 2.08 mg/mL (6.45 mM); Clear solution			
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: \geq 2.08 mg/mL (6.45 mM); Clear solution			

BIOLOGICAL ACTIVITY

Description	FzM1.8 derives from FzM1, is an allosteric agonist of FZD4 with pEC ₅₀ of 6.4. FzM1.8 binds to FZD4 and activates the WNT/ β -catenin pathway, by promoting TCF/LEF transcriptional activity in the absence of any WNT ligand. FzM1.8 binding stabilizes FZD4 with an increased affinity for heterotrimeric G protein and stimulates the release of the G $\beta\gamma$ subunit that in turn activates PI3K ^[1] .
IC ₅₀ & Target	pEC ₅₀ : 6.4 (FzM1.8) ^[1]

REFERENCES

[1]. Riccio G, et al. A Negative Allosteric Modulator of WNT Receptor Frizzled 4 Switches into an Allosteric Agonist. *Biochemistry*. 2018 Feb 6;57(5):839-851.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA